Literature DB >> 2944474

Effect of recombinant human fibroblast interferon and mezerein on growth, differentiation, immune interferon binding and tumor associated antigen expression in human melanoma cells.

P B Fisher, H Hermo, W E Solowey, M C Dietrich, G M Edwalds, I B Weinstein, J A Langer, S Pestka, P Giacomini, M Kusama.   

Abstract

The combination of recombinant human fibroblast interferon (INF-delta) and the antileukemic compound mezerein (MEZ) results in a synergistic suppression in the growth of human melanoma cells and a concomitant increase in melanin synthesis. In the present study we have further analyzed this synergistic interaction and have also evaluated the effect of IFN-delta and MEZ, alone and in combination, on recombinant human gamma interferon (IFN-gamma) binding and Class I HLA and melanoma associated antigen (MAA) expression in the HO-1 human melanoma cell line. Single cell clones isolated from the HO-1 cell line varied in their sensitivity to the antiproliferative effects of IFN-delta and MEZ. With all twelve clones, however, the combination of IFN-delta plus MEZ was more growth inhibitory than either agent used alone, even in HO-1 subclones displaying relative resistance to IFN-delta. By continuous growth in gradually increasing concentrations of IFN-delta, a variant population of HO-1 cells, HO-1 delta R-D, was generated which was more resistant to the antigrowth effects of IFN-delta than the original HO-1 parental cell line. In the IFN delta R-D cell line the combination of IFN-delta plus MEZ synergistically suppressed growth. Exposure of HO-1 cells to 2500 units/ml IFN-delta or 50 ng/ml MEZ for 96 hr resulted in no change or an increase in the binding of labelled IFN-gamma to surface receptors, whereas the combination of IFN-delta plus MEZ increased IFN-gamma binding 2-to-4-fold in HO-1 cells. This increase was the result of an increase in the number of receptors on treated cells coupled with a protection against a decrease in receptors observed for confluent untreated cells. Changes in IFN-gamma binding resulting from treatment with IFN-delta plus MEZ were not associated with alterations in the binding affinity of INF-gamma to its receptor. Changes were also observed in the expression of HLA Class I antigens and MAAs following treatment of HO-1 cells with IFN-delta, MEZ or IFN-delta plus MEZ. IFN-delta and MEZ increased the expression of HLA Class I antigens a 96 kd MAA defined by MoAb CL203, a 100 kd MAA defined by MoAb 376.96 and a 115 kd MAA defined by MoAb 345.134 but decreased the expression of a high molecular weight-melanoma associated antigen (HMW-MAA) defined by MoAb 325.28S.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2944474

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Potentiation of growth suppression and modulation of the antigenic phenotype in human melanoma cells by the combination of recombinant human fibroblast and immune interferons.

Authors:  G M Graham; L Guarini; T A Moulton; S Datta; S Ferrone; P Giacomini; R S Kerbel; P B Fisher
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Cloning and characterization of SARI (suppressor of AP-1, regulated by IFN).

Authors:  Zao-zhong Su; Seok-Geun Lee; Luni Emdad; Irina V Lebdeva; Pankaj Gupta; Kristoffer Valerie; Devanand Sarkar; Paul B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-12       Impact factor: 11.205

3.  In vitro differentiation and antigenic changes in human melanoma cell lines.

Authors:  L Guarini; M Temponi; G M Edwalds; J R Vita; P B Fisher; S Ferrone
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 4.  Chapter One---Cancer terminator viruses and approaches for enhancing therapeutic outcomes.

Authors:  Swadesh K Das; Siddik Sarkar; Rupesh Dash; Paul Dent; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

Review 5.  Human polynucleotide phosphorylase (hPNPase(old-35)): an evolutionary conserved gene with an expanding repertoire of RNA degradation functions.

Authors:  S K Das; S K Bhutia; U K Sokhi; R Dash; B Azab; D Sarkar; P B Fisher
Journal:  Oncogene       Date:  2010-12-13       Impact factor: 9.867

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.